← All stories
● Covered by 1 source · 1 reportLow impact1 neutral

CDC Study: Millions of Americans Misuse GLP-1 Drugs Due to Cost and Availability

🔄 Updated 8d ago
New to BrevFeed? We gather this story from every outlet covering it into one summary — ranked by real-world impact, not just the latest headline — so you never miss what matters. What is BrevFeed? →

Key points

  • 9.8% of US adults used GLP-1 medications in 2025, totaling 27 million.
  • 44% of GLP-1 users modified their prescribed usage.
  • Cost and availability were the main reasons for modified use.
  • 23% of users took compounded GLP-1 versions.

Prevalence of GLP-1 Medication Use

A study by the Centers for Disease Control and Prevention (CDC) analyzed survey data from July to August 2025, involving over 8,000 US adults. The findings indicate that approximately 9.8% of US adults, or about 27 million people, used a glucagon-like peptide-1 receptor agonist (GLP-1 medication) in 2025. This data was published in the CDC’s Morbidity and Mortality Weekly Report.

Widespread Non-Adherence to Prescriptions

The study revealed that nearly half (44%) of GLP-1 users reported taking their medication differently than prescribed. This included actions such as skipping doses, delaying refills, or using smaller doses. This suggests a significant portion of users are not following medical instructions for these potent drugs.

Cost and Access as Primary Barriers

More than half of individuals who modified their GLP-1 usage attributed these changes to issues with cost or drug availability. These barriers were particularly pronounced among younger users; 58% of adults aged 14–39 cited cost as a reason for modifying use, compared to 20% of adults 65 or older.

Use of Compounded Versions

The study also highlighted the use of compounded GLP-1 medications. Among all GLP-1 users, at least 23% reported using a compounded version. An additional 9% were unsure whether their medication was compounded, indicating a lack of clarity for some users regarding their drug's origin.

Implications for Safety and Efficacy

The widespread modified use of GLP-1 drugs, especially with unapproved or compounded versions, raises questions about the real-world safety and efficacy of these medications. Deviations from prescribed regimens can impact treatment outcomes and potentially introduce unforeseen health risks.

✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →

The daily brief

One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.

One email a day. Unsubscribe in one click, any time.

Today's brief

Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.

~4 min · 3 stories · Nov 21

▶ Play today's brief Listen on Spotify

New every morning, and the back catalogue is archived by date.

Reporting from

A CDC study found that nearly half of GLP-1 medication users in the US, approximately 12 million adults, are not taking their drugs as prescribed. The primary reasons cited for modified use were cost and availability, with younger adults more affected by cost barriers.